ANSWER: E

Rationale:

The pharmacokinetic distinction between nafcillin and oxacillin is clinically important in patients with severely impaired or absent renal function. Nafcillin is the antistaphylococcal penicillin with predominantly hepatic elimination: approximately 70–80% of a nafcillin dose is excreted in bile as unchanged drug or metabolites, with renal elimination accounting for only a minor fraction. This hepatobiliary clearance pathway is independent of renal function, meaning that in a patient on hemodialysis with near-absent residual renal function, nafcillin's half-life and steady-state concentrations are essentially unchanged from those in a patient with normal renal function — no dose adjustment is required. Oxacillin, by contrast, undergoes both renal and hepatic elimination; while it is more forgiving than renally-cleared beta-lactams such as piperacillin-tazobactam or ampicillin, oxacillin clearance is partially renal-dependent and some degree of accumulation can occur in severe or end-stage renal failure, potentially requiring monitoring or adjustment. For a patient with MSSA bacteremia who should receive an antistaphylococcal penicillin — the treatment of choice for MSSA, superior to vancomycin in outcomes — nafcillin is the pharmacokinetically rational choice when renal function is severely impaired.

• Option A: Option A is incorrect: nafcillin is not significantly removed by hemodialysis because its hepatic elimination produces biliary drug that is not in the intravascular compartment available for dialysis clearance; dialysis supplemental dosing is not a relevant consideration for nafcillin and the premise misrepresents its pharmacokinetics.
• Option B: Option B is incorrect: oxacillin is not contraindicated in hemodialysis patients due to membrane adsorption; while some drugs do adsorb to dialysis membranes, this is not an established clinically significant problem for oxacillin; the reason to prefer nafcillin in renal failure is pharmacokinetic (elimination route), not membrane chemistry.
• Option C: Option C is incorrect: nafcillin does not have superior biofilm penetration compared to oxacillin through any established pharmacokinetic mechanism; both agents are highly protein-bound and penetrate biofilm-associated infections with similar limitations; biofilm penetration is not the basis for selecting between antistaphylococcal penicillins.
• Option D: Option D is incorrect: nafcillin and oxacillin are not pharmacokinetically interchangeable in dialysis patients; the distinction in elimination route — hepatic for nafcillin versus mixed for oxacillin — is clinically meaningful in this setting; the preference for nafcillin in renal failure is pharmacokinetically based, not merely an institutional formulary preference.

ANSWER: C

Rationale:

Neurosyphilis requires aqueous crystalline penicillin G administered intravenously at high doses — 18 to 24 million units per day — for 10 to 14 days. The pharmacological rationale integrates several principles. First, achieving treponemicidal CSF concentrations requires overcoming the blood-brain barrier: under normal conditions penicillin CSF-to-plasma ratios are approximately 1–2%, and even with meningeal inflammation the ratio rises to only approximately 5–10%. To achieve a CSF concentration above the MIC for Treponema pallidum requires driving high plasma concentrations — only the high-dose intravenous aqueous formulation reliably achieves this. Second, aqueous penicillin G has a short half-life (approximately 30 minutes) and plasma concentrations decline rapidly; to maintain sustained CSF concentrations above the treponemicidal threshold, dosing must be either continuous or at frequent intervals (every 4 hours). Benzathine penicillin G — the standard formulation for early syphilis — produces sustained low-level plasma concentrations adequate for treponemal eradication in non-CNS compartments but does not achieve CSF concentrations sufficient for neurosyphilis. This is the definitive pharmacological distinction: benzathine is appropriate for early syphilis (where treponemes are extravascularly accessible at low drug concentrations), but fails neurosyphilis for which CSF penetration at treponemicidal concentrations requires the high sustained plasma levels only achievable with high-dose intravenous aqueous penicillin G. CDC guidelines specify this regimen and recommend desensitization for penicillin-allergic patients with neurosyphilis rather than using alternative antibiotics, because no alternative has demonstrated equivalent CNS efficacy.

• Option A: Option A is incorrect: benzathine penicillin G produces very low plasma concentrations (designed to provide slow-release sustained low levels) and does not achieve adequate CSF concentrations for neurosyphilis; this is not compensated by steady-state kinetics; CSF concentrations of benzathine penicillin have been directly measured and found to be below treponemicidal thresholds; CDC guidelines explicitly contraindicate benzathine penicillin for neurosyphilis.
• Option B: Option B is incorrect: oral penicillin V does not achieve the plasma concentrations needed to drive adequate CSF penetration for neurosyphilis; the bioavailability limitation and peak concentration limitations of oral dosing make it unreliable for CNS infection; there is no clinical evidence supporting oral penicillin V as equivalent to intravenous penicillin G for neurosyphilis.
• Option D: Option D is incorrect: procaine penicillin G plus probenecid is an alternative regimen mentioned in some guidelines as a second-line option when intravenous access is not available, but it is not the preferred regimen; the mechanism described — probenecid enhancing active choroid plexus transport into CSF — inverts the actual pharmacology; probenecid inhibits OAT-mediated efflux of penicillin FROM the CSF, potentially increasing CSF residence time, but choroid plexus active transport INTO the CSF is not enhanced by probenecid.
• Option E: Option E is incorrect: doxycycline is a tetracycline with better CNS penetration than penicillin G in relative terms, but it has not been proven equivalent to intravenous penicillin G for neurosyphilis; CDC guidelines specifically state that doxycycline should not be used for neurosyphilis when the diagnosis is confirmed; in HIV-infected patients, the risk of inadequate treatment of neurosyphilis is particularly high, making departures from established penicillin regimens inappropriate.

ANSWER: A

Rationale:

This patient presents with urosepsis — not uncomplicated UTI — with multiple established risk factors for ESBL-producing Enterobacteriaceae: prior fluoroquinolone exposure (fluoroquinolones co-select with ESBL plasmids through shared mobile genetic elements), prior sulfonamide exposure (similarly co-selects for resistance plasmids), diabetes mellitus (recurrent infections requiring antibiotic courses amplify resistant organism selection), and recent healthcare contact in India (a region with some of the highest global ESBL prevalence rates, often exceeding 60–70% in hospitalized patients). In a septic patient with this pre-test probability of ESBL, empiric carbapenem therapy is clinically appropriate. The MERINO trial's definitive finding — 12.3% 30-day mortality with piperacillin-tazobactam versus 3.7% with meropenem for ESBL bacteremia — means that starting pip-tazo empirically in a high-risk patient and waiting for culture confirmation creates a window in which a patient with ESBL bacteremia receives inadequate definitive coverage. Ertapenem is a carbapenem with adequate gram-negative and anaerobic coverage for urosepsis that can be dosed once daily and does not cover Pseudomonas (an advantage in preserving meropenem/imipenem for organisms requiring antipseudomonal activity). De-escalation to a narrower agent should occur once susceptibility data are available.

• Option B: Option B is incorrect: empirically using pip-tazo while "reserving carbapenems" misapplies antibiotic stewardship principles to a septic patient with high ESBL probability; antibiotic stewardship supports appropriate empiric therapy — including carbapenems when clinically indicated — followed by de-escalation; withholding carbapenems in a septic high-risk ESBL patient to prevent resistance emergence prioritizes population-level stewardship over individual patient safety in a situation where the risk is acute.
• Option C: Option C is incorrect: third-generation cephalosporins are exactly the agents hydrolyzed by ESBLs; using ceftriaxone in a patient with high ESBL probability provides the least appropriate empiric coverage for this clinical scenario; furthermore, ESBL prevalence varies substantially by geography and risk profile and cannot be dismissed based on aggregate community statistics when individual risk is high.
• Option D: Option D is incorrect: the patient has prior ciprofloxacin exposure for recurrent UTIs — this is precisely the scenario in which fluoroquinolone resistance should be assumed; fluoroquinolone resistance in E. coli is strongly associated with ESBL co-carriage; repeating the antibiotic class most likely to have selected for resistant organisms is clinically inappropriate for a septic patient.
• Option E: Option E is incorrect: while cefepime does have improved stability against chromosomal AmpC compared to third-generation cephalosporins, it is susceptible to hydrolysis by ESBLs at high enzyme concentrations; additionally, the most likely resistance mechanism in this patient — given the epidemiological risk factors — is ESBL in E. coli, not AmpC derepression in Enterobacter; the epidemiological framing is inverted.

ANSWER: D

Rationale:

MRSA resistance to all beta-lactam antibiotics — including piperacillin-tazobactam — is mediated by PBP2a, a modified transpeptidase encoded by the mecA gene carried on the mobile SCCmec (staphylococcal cassette chromosome mec) element. Unlike native staphylococcal PBPs (PBP1, PBP2, PBP3, PBP4), which are efficiently acylated and permanently inactivated by beta-lactam antibiotics at clinical drug concentrations, PBP2a has a structurally altered active site that reduces its affinity for beta-lactams to levels far below what can be achieved clinically. PBP2a retains full transpeptidase catalytic activity at clinical piperacillin concentrations, allowing MRSA to continue cross-linking peptidoglycan and proliferating despite drug exposure. Tazobactam's beta-lactamase inhibitory activity is irrelevant to this mechanism — PBP2a is not a beta-lactamase and is not inhibited by tazobactam. For MRSA pneumonia, vancomycin is the standard of care: it targets the D-Ala-D-Ala terminus of the lipid II peptidoglycan precursor by physical binding rather than PBP acylation, a mechanism that is unaffected by PBP2a expression. Alternatively, linezolid (an oxazolidinone that inhibits bacterial protein synthesis) has demonstrated non-inferior outcomes to vancomycin for MRSA pneumonia in clinical trials.

• Option A: Option A is incorrect: tazobactam does not compete with piperacillin for PBP binding sites; tazobactam is a beta-lactamase inhibitor that acylates beta-lactamase active-site serines, not PBP transpeptidase active sites; the premise of competitive PBP inhibition by tazobactam reducing piperacillin's efficacy against MRSA is pharmacologically incorrect.
• Option B: Option B is incorrect: MRSA's beta-lactam resistance is not mediated by a TEM-type ESBL; TEM-type ESBLs are class A serine beta-lactamases found predominantly in gram-negative organisms; MRSA resistance is mediated by PBP2a, a modified transpeptidase, not by beta-lactamase production; carbapenems are equally ineffective against MRSA for the same reason as piperacillin — PBP2a.
• Option C: Option C is incorrect: it is partially true that ceftaroline (a fifth-generation cephalosporin) retains affinity for PBP2a and has clinical activity against MRSA; however, the reason piperacillin lacks PBP2a affinity is not specifically the piperazinyl side chain — all beta-lactams lack adequate PBP2a affinity except ceftaroline and ceftobiprole; additionally, the option incorrectly suggests tazobactam provides useful continuing co-activity, which is irrelevant since tazobactam cannot inhibit PBP2a.
• Option E: Option E is incorrect: MRSA does not lack PBPs and has not replaced its cell wall synthesis with a beta-lactam-independent pathway; MRSA expresses all its native PBPs plus the additional PBP2a; vancomycin works through cell wall precursor binding, not by inhibiting transglycosylation specifically; the description of vancomycin resistance in MRSA conflates VRSA and VISA mechanisms with a mechanism that does not exist.

ANSWER: B

Rationale:

This case illustrates the classic and clinically well-documented phenomenon of on-therapy AmpC derepression in Enterobacter cloacae. E. cloacae, along with other ESCAPPM organisms, harbors a chromosomally encoded AmpC cephalosporinase whose expression is normally maintained at low levels by an AmpR repressor. Mutations in AmpR or in the AmpD enzyme (which degrades the cell wall fragment that acts as the AmpC-inducing signal) produce stably derepressed mutants that constitutively overexpress AmpC at levels sufficient to hydrolyze third-generation cephalosporins including ceftriaxone. These mutants pre-exist in the wild-type bacterial population at a frequency of approximately 1 in 10⁶ to 10⁷ bacteria; under selection pressure from ceftriaxone therapy, susceptible wild-type bacteria are killed while the derepressed mutants — which the original susceptibility testing did not detect because the inoculum was below their representation frequency — proliferate and repopulate the bacteremia. The derepressed AmpC enzyme efficiently hydrolyzes ceftriaxone and piperacillin (piperacillin is also an AmpC substrate), explaining the co-resistance; piperacillin-tazobactam resistance reflects AmpC-mediated piperacillin hydrolysis that tazobactam cannot suppress (tazobactam does not inhibit class C AmpC). Cefepime retains activity because its zwitterionic fourth-generation structure makes it a poor AmpC substrate at typical enzyme concentrations — its dipolar charge promotes rapid periplasmic penetration, it has low affinity for AmpC, and it is only a weak inducer. Carbapenems retain full activity because they are not AmpC substrates. Treatment should switch to either cefepime or a carbapenem.

• Option A: Option A is incorrect: the resistance pattern described — ceftriaxone and piperacillin-tazobactam resistance with preserved cefepime and carbapenem susceptibility — is the characteristic signature of AmpC derepression, not ESBL acquisition; TEM-type ESBLs are class A enzymes inhibited by clavulanate and would typically not produce resistance to pip-tazo with preserved cefepime susceptibility; additionally, cefepime can be hydrolyzed by some ESBL variants but is generally stable against TEM ESBLs at standard concentrations.
• Option C: Option C is incorrect: ceftriaxone does not produce significant DNA double-strand breaks as a mechanism of action — beta-lactams act on PBPs, not DNA; the SOS response mechanism described, while real for fluoroquinolones (which do cause DNA damage), is not the mechanism by which ceftriaxone selects for resistance in Enterobacter; AmpR derepression through chromosomal mutation, not SOS-mediated mutagenesis, is the established mechanism.
• Option D: Option D is incorrect: the resistance pattern described is not consistent with porin downregulation; porin loss generally produces broad resistance across multiple antibiotic classes and would not selectively spare cefepime while producing ceftriaxone resistance; AmpC derepression produces the selective resistance pattern described; probenecid does not prevent porin downregulation and has no role in managing this patient.
• Option E: Option E is incorrect: OprD porin loss is a resistance mechanism in Pseudomonas aeruginosa, not Enterobacter cloacae; Enterobacter uses OmpF and OmpC, not OprD; additionally, OprD loss in Pseudomonas specifically affects carbapenem susceptibility (imipenem, meropenem), not ceftriaxone susceptibility; the assignment of OprD biology to Enterobacter is a factual error.

ANSWER: E

Rationale:

This clinical scenario precisely illustrates the rationale for extended infusion piperacillin-tazobactam. The key pharmacodynamic principle is that beta-lactams exhibit time-dependent killing: the parameter predicting bactericidal efficacy is fT>MIC — the percentage of the dosing interval during which free drug concentration exceeds the MIC — not peak concentration. For a standard 30-minute infusion of 4.5 g pip-tazo, drug is administered rapidly, producing a high peak followed by exponential decline. In a patient with normal renal function receiving every 6-hour dosing, the half-life of piperacillin is approximately 1 hour; by 4–5 hours into the dosing interval, free drug concentrations may fall substantially below 16 mcg/mL, particularly in a critically ill patient with augmented renal clearance (a common phenomenon in ICU patients where glomerular filtration and tubular secretion are supranormal). For a standard infusion, the fT>MIC may be 40–50% — marginal for bactericidal activity and inadequate in patients with augmented clearance. Extending the infusion to 4 hours produces a flatter concentration-time profile: peak is lower but concentrations remain above 16 mcg/mL for a much greater proportion of the 6-hour interval. Multiple pharmacokinetic-pharmacodynamic modeling studies and several retrospective clinical studies have demonstrated improved target attainment and clinical cure rates with extended infusion piperacillin-tazobactam for organisms at or near the susceptibility breakpoint. In a critically ill ventilated patient where treatment failure is life-threatening, this pharmacodynamic optimization is clinically meaningful.

• Option A: Option A is incorrect: being "at or below the susceptibility breakpoint" does not guarantee adequate fT>MIC for all patients; the susceptibility breakpoint is defined for a population but individual patients — particularly the critically ill with augmented renal clearance, altered volumes of distribution, or high MIC organisms at the breakpoint — may not achieve target attainment with standard infusion; the pharmacist's recommendation is precisely aimed at the MIC 16 mcg/mL scenario.
• Option B: Option B is incorrect: the primary pharmacodynamic rationale for extended infusion is improved fT>MIC and target attainment, not toxicity reduction; piperacillin-tazobactam does not cause significant nephrotoxicity as a primary toxicity concern at standard doses; the framing of benefit as "safety rather than pharmacodynamic" inverts the clinical rationale.
• Option C: Option C is incorrect: AUC/MIC is the pharmacodynamic driver for fluoroquinolones and vancomycin, not beta-lactams; for beta-lactams, fT>MIC is the key parameter; extending the infusion does change the pharmacodynamic outcome (more time above MIC) even without changing total dose or AUC; this option misidentifies the pharmacodynamic index for beta-lactams.
• Option D: Option D is incorrect: pulmonary epithelial lining fluid pharmacokinetics do track plasma pharmacokinetics for piperacillin, and improved plasma fT>MIC with extended infusion does translate to improved epithelial lining fluid concentrations above the MIC; the assertion that plasma pharmacodynamic advantages are irrelevant to lung concentrations contradicts established pulmonary pharmacokinetic data for beta-lactams.

ANSWER: C

Rationale:

Dicloxacillin is an isoxazolyl antistaphylococcal penicillin with an important and clinically consequential food-absorption interaction. Unlike amoxicillin — whose absorption is minimally affected by food (a key reason for its clinical preference over ampicillin for oral use) — dicloxacillin absorption is significantly reduced in the fed state. When taken with a meal, gastric emptying slows, prolonging the time the drug spends in the stomach and altering the rate and extent of intestinal transport. Published pharmacokinetic studies have demonstrated that the Cmax (peak plasma concentration) and AUC of dicloxacillin can decrease by 50% or more when taken with food compared to the fasted state. Because dicloxacillin's efficacy, like all beta-lactams, is governed by fT>MIC, lower plasma concentrations directly reduce the time during which free drug exceeds the MSSA MIC, potentially falling below the therapeutic threshold needed for bactericidal activity. This patient's clinical failure despite apparent compliance is explained by this pharmacokinetic interaction: she took the correct dose at the correct interval but inadvertently bypassed adequate bioavailability by taking the drug with meals. Management should include counseling to take dicloxacillin on an empty stomach — at least 30–60 minutes before meals or 2 hours after eating.

• Option A: Option A is incorrect: dicloxacillin is an active drug, not a prodrug requiring hepatic activation; it is administered as the active form and does not require esterase cleavage; the concept of postprandial hepatic blood flow diversion affecting prodrug activation does not apply to dicloxacillin.
• Option B: Option B is incorrect: taking dicloxacillin with food decreases, not increases, its absorption; the premise of rapid dissolution in the fed stomach producing paradoxically lower time above MIC is pharmacokinetically incorrect; the fed state reduces Cmax and AUC for dicloxacillin, not redistributes the same bioavailability into a shorter peak.
• Option D: Option D is incorrect: amoxicillin does not select for mecA-carrying MSSA subpopulations; mecA acquisition is not co-selected by prior aminopenicillin exposure; if the initial culture showed MSSA without mecA, a subsequent culture after amoxicillin treatment would not reliably yield mecA-positive organisms through selection by that mechanism; additionally, a single prior course of amoxicillin for a different indication would not predictably produce this resistance emergence.
• Option E: Option E is incorrect: dicloxacillin does achieve therapeutic soft tissue concentrations for skin infections; while its protein binding is high (approximately 95–97%), free drug concentrations at standard doses do penetrate soft tissue adequately for MSSA skin infections; the premise that high protein binding limits distribution to the intravascular space to the point of clinical failure for skin infections contradicts clinical experience with dicloxacillin as an established treatment for MSSA skin infections when properly administered.

ANSWER: A

Rationale:

This clinical scenario illustrates the appropriate application of modern penicillin-cephalosporin cross-reactivity evidence. The historically cited 10% cross-reactivity figure originated from 1960s studies using penicillin preparations contaminated with penicilloic acid polymers that were independently immunogenic; modern high-purity penicillin preparations produce substantially less sensitization, and prospective studies now consistently estimate true penicillin-cephalosporin cross-reactivity at approximately 1–2%. Critically, the mechanistically relevant determinant of cross-reactivity is the R1 side chain — the acyl substituent attached to the beta-lactam — not the bicyclic ring system alone. Penicillin allergy at age 12 presenting as hives was most likely caused by aminopenicillins (ampicillin, amoxicillin) which were commonly prescribed in childhood for ear infections and pharyngitis and share an aminobenzyl R1 group that is immunodominant in forming penicilloyl haptens. Cefazolin's R1 side chain (a tetrazolylthiomethyl group) is structurally dissimilar from the aminobenzyl group — cross-reactivity between aminopenicillins and cefazolin is lower than between structurally homologous penicillin-cephalosporin pairs. For a patient with a non-anaphylactic childhood rash (hives without anaphylaxis, angioedema, or respiratory compromise), current AAAAI (American Academy of Allergy, Asthma and Immunology) and IDSA guidance supports administering a structurally dissimilar cephalosporin with appropriate monitoring rather than reflexively avoiding all beta-lactams.

• Option B: Option B is incorrect: urticaria does not confirm a definitive IgE-mediated allergy that guarantees future anaphylaxis; many patients with historic "penicillin allergy" labels do not have demonstrable IgE sensitization on formal testing; characterizing urticaria as equivalent to confirmed anaphylaxis overstates the risk; the beta-lactam ring is not the universal sole cross-reactive epitope; and vancomycin is pharmacologically inferior to beta-lactams for MSSA.
• Option C: Option C is incorrect: while it is true that penicillin and cephalosporin ring systems differ structurally, stating there is "zero immunological cross-reactivity" between the classes overstates the case in the opposite direction; a small but real cross-reactivity risk exists (approximately 1–2%) and dismissing it entirely could result in inadequate preparation for management of a rare reaction; proceeding without precautions or monitoring is not appropriate clinical practice.
• Option D: Option D is incorrect: penicillin skin testing with PPL does not have 95% sensitivity for predicting all beta-lactam cross-reactivity; PPL testing predicts major determinant IgE sensitization but does not predict reactions to specific cephalosporins based on R1 side chain differences; requiring formal skin testing before any cephalosporin is overly restrictive and not standard practice for patients with low-risk penicillin allergy histories.
• Option E: Option E is incorrect: the scenario described — a 45-year-old with a childhood rash, non-anaphylactic history — does not require a full graded cephalosporin challenge in an ICU setting as the mandatory prerequisite for cefazolin administration; graded challenges are appropriate for higher-risk situations; this option imposes a restriction not consistent with current clinical practice guidelines for low-risk penicillin allergy.

ANSWER: D

Rationale:

KPC (Klebsiella pneumoniae carbapenemase) is an Ambler class A serine carbapenemase — it uses the hydroxyl group of an active-site serine to form a covalent acyl-enzyme intermediate with the beta-lactam carbonyl, then deacylates to release the hydrolyzed (inactivated) antibiotic. This enzymatic process efficiently inactivates meropenem and other carbapenems, producing high-level carbapenem resistance (MIC often exceeding 64 mcg/mL) that cannot be overcome by dose escalation because no clinically achievable meropenem concentration exceeds the enzyme's hydrolytic capacity. Avibactam is a diazabicyclooctane (DBO) non-beta-lactam beta-lactamase inhibitor that forms a covalent carbamyl-enzyme intermediate with the KPC active-site serine, inactivating the enzyme. Unlike clavulanate and tazobactam, avibactam's carbamylation is reversible — avibactam can eventually deacylate and regenerate active inhibitor — but the equilibrium strongly favors the inhibited enzyme at clinical concentrations, effectively suppressing KPC activity. With KPC inhibited by avibactam, ceftazidime (a third-generation cephalosporin that would otherwise be rapidly hydrolyzed by KPC) can accumulate in the periplasm and inhibit PBP3, the essential cell division transpeptidase in Klebsiella, producing bactericidal killing. Ceftazidime-avibactam has clinical outcome data supporting efficacy against KPC-producing CRE (carbapenem-resistant Enterobacterales) from multiple case series and prospective registries.

• Option A: Option A is incorrect: OprD porin loss is a mechanism in Pseudomonas aeruginosa, not Klebsiella pneumoniae; Klebsiella uses OmpK35 and OmpK36 as outer membrane porins; while porin loss does contribute to carbapenem resistance in KPC-producing Klebsiella in some strains, the primary mechanism in this question is KPC carbapenemase activity; additionally, ceftazidime uses OmpF-type channels in Enterobacteriaceae, not OprD.
• Option B: Option B is incorrect: ceftazidime is not inherently resistant to KPC hydrolysis; KPC efficiently hydrolyzes third-generation cephalosporins including ceftazidime — this is one of the defining features of KPC that distinguishes it from ESBLs; the essential function of avibactam is to protect ceftazidime by inhibiting KPC, not merely to address co-existing ESBLs.
• Option C: Option C is incorrect: MexAB-OprM is a Pseudomonas aeruginosa efflux system and is not expressed by Klebsiella pneumoniae; KPC-producing Klebsiella do have efflux systems but MexAB-OprM is not among them; attributing meropenem failure to MexAB-OprM in Klebsiella is a fundamental organism-specific error.
• Option E: Option E is incorrect: meropenem treatment does not induce PBP mutations in Klebsiella that reduce carbapenem affinity while preserving cephalosporin affinity; this mechanism of adaptive PBP remodeling does not occur in Klebsiella as a clinically relevant resistance emergence pathway during carbapenem therapy; carbapenem resistance in KPC producers is pre-existing enzymatic resistance, not treatment-induced PBP mutation.

ANSWER: B

Rationale:

This patient has E. faecalis endocarditis with confirmed gentamicin HLAR (MIC 768 mcg/mL, well above the 500 mcg/mL threshold). HLAR is defined by the MIC threshold that predicts complete loss of aminoglycoside synergy — when the gentamicin MIC exceeds 500 mcg/mL, aminoglycoside-modifying enzymes are present that inactivate gentamicin before it can reach the 30S ribosomal subunit in concentrations sufficient for bactericidal contribution, even when cell wall permeability is enhanced by ampicillin. The ampicillin-gentamicin synergistic regimen therefore cannot be used. Two appropriate alternatives exist. First, ampicillin plus streptomycin: streptomycin HLAR threshold is 2000 mcg/mL (different threshold from gentamicin), and this isolate's streptomycin MIC of 128 mcg/mL is well below this threshold, indicating that the specific aminoglycoside-modifying enzymes that inactivate gentamicin do not inactivate streptomycin; streptomycin synergy with ampicillin is therefore likely preserved. Second, ampicillin plus ceftriaxone: this double beta-lactam regimen achieves bactericidal killing through PBP saturation — ampicillin inhibits PBP1–3 while ceftriaxone inhibits PBP4 and PBP5 (lower-affinity PBPs that ampicillin cannot efficiently suppress at standard doses) — producing more complete inhibition of peptidoglycan cross-linking that overcomes enterococcal tolerance without requiring aminoglycoside synergy. This regimen is recommended by IDSA guidelines for E. faecalis endocarditis when both aminoglycosides are HLAR.

• Option A: Option A is incorrect: a gentamicin MIC of 768 mcg/mL on standardized HLAR testing (using a specific high-concentration gentamicin disk or broth dilution at 500 mcg/mL) is not a testing artifact; the HLAR threshold is specifically defined to predict loss of synergy and is a reliable clinical predictor; proceeding with ampicillin-gentamicin when confirmed HLAR is present would result in ampicillin monotherapy without the bactericidal synergistic contribution needed for endocarditis cure.
• Option C: Option C is incorrect: vancomycin plus gentamicin does not achieve synergistic bactericidal killing equivalent to ampicillin-gentamicin; vancomycin's cell wall disruption does not enhance aminoglycoside uptake to the same extent as beta-lactam-mediated cell wall inhibition; additionally, HLAR abolishes gentamicin synergy regardless of which cell wall-active partner is used — the aminoglycoside-modifying enzyme inactivates gentamicin independently of the mechanism of cell wall disruption.
• Option D: Option D is incorrect: ampicillin monotherapy at high dose does not reliably achieve bactericidal killing against enterococci for endocarditis; the MBC greatly exceeds achievable plasma concentrations regardless of dose escalation; this is the defining characteristic of enterococcal tolerance that necessitates synergistic combination therapy for endocarditis.
• Option E: Option E is incorrect: while daptomycin-ampicillin combinations have been used in salvage settings for enterococcal endocarditis and some data support benefit in refractory cases, this combination is not the first-line IDSA-recommended regimen for HLAR enterococcal endocarditis; the current IDSA guideline-recommended options are ampicillin-streptomycin (if streptomycin not HLAR) and ampicillin-ceftriaxone.

ANSWER: C

Rationale:

This presentation is a classic and preventable case of penicillin G neurotoxicity from drug accumulation in renal failure. The mechanism integrates several pharmacological principles. Penicillin G is predominantly renally eliminated — approximately 60–90% of each dose is excreted as unchanged drug through a combination of glomerular filtration and OAT1-mediated active tubular secretion. In a patient with an eGFR of 22 mL/min (stage 4 CKD), renal clearance of penicillin G is reduced to approximately 15–20% of normal. Without dose adjustment over 4 days of every 4-hour dosing, penicillin G accumulates progressively, with steadily rising trough and peak concentrations. Simultaneously, this patient has pneumococcal meningitis — the very indication for high-dose penicillin G — which has increased blood-brain barrier permeability through disruption of tight junctions and downregulation of efflux transporters, substantially elevating the CSF-to-plasma drug ratio from the normal 1–2% to approximately 5–10%. The combination of very high plasma concentrations (from renal accumulation) and increased CNS penetration (from meningeal inflammation) drives CSF penicillin concentrations to levels that produce pharmacological toxicity at GABA-A receptors: penicillin G competitively antagonizes GABA-A chloride channel conductance, reducing inhibitory GABAergic tone throughout the CNS and producing a syndrome of myoclonus, asterixis, encephalopathy, and — at higher concentrations — generalized tonic-clonic seizures. Management requires immediate dose reduction (typically increasing the dosing interval or halving the dose based on eGFR), close monitoring for progression to seizures, and potentially discontinuing and restarting at an adjusted dose after plasma concentrations fall.

• Option A: Option A is incorrect: worsening of meningitis with cortical involvement is possible but the clinical context — improvement from meningitis followed by new stereotyped myoclonus on day 4 without fever recurrence or focal neurological deficits — strongly favors drug neurotoxicity over meningitis progression; on-therapy resistance emergence in pneumococcal meningitis is uncommon with appropriate beta-lactam therapy; adding vancomycin-rifampin without recognizing the pharmacokinetic cause delays correct management.
• Option B: Option B is incorrect: while uremia can produce encephalopathy, the abrupt onset of myoclonus — a specific motor finding — on day 4 of high-dose penicillin G without dose adjustment in a patient with known CKD is the classic presentation of penicillin neurotoxicity; attributing the finding solely to uremia and continuing penicillin G without dose adjustment risks progression to generalized seizures; the temporal relationship and clinical context strongly implicate drug accumulation.
• Option D: Option D is incorrect: the stem does not mention concurrent cefazolin; introducing a drug not mentioned in the clinical scenario as the cause of neurotoxicity is inappropriate reasoning; penicillin G neurotoxicity in CKD is the parsimonious and pharmacologically supported explanation.
• Option E: Option E is incorrect: penicillin G does not inhibit serotonin reuptake transporters and does not cause serotonin syndrome; penicillin's neurological toxicity is mediated through GABA-A antagonism, not serotonergic mechanisms; cyproheptadine is not an appropriate treatment for penicillin neurotoxicity.